11. Agreement analysis: number needed to biopsy.
| Agreement analysis: number needed to biopsy by systematic biopsy to detect one extra prostate cancer not detected by the MRI‐pathway | |||
| Population | Target condition | NNBa (95% CI) | |
| Biopsy status | MRI | ||
| Biopsy‐naïve | Positive | G = 1 | 24 (15 to 40) |
| G ≥ 2 | 20 (12 to 36) | ||
| G ≥ 3 | 27 (16 to 45) | ||
| Negative | G = 1 | 5 (4 to 7) | |
| G ≥ 2 | 13 (9 to 18) | ||
| G ≥ 3 | 33 (18 to 63) | ||
| Prior‐negative biopsy | Positive | G = 1 | 33 (13 to 100) |
| G ≥ 2 | 37 (18 to 83) | ||
| G ≥ 3 | 83 (31 to 250) | ||
| Negative | G = 1 | 7 (3 to 17) | |
| G ≥ 2 | 19 (11 to 32) | ||
| G ≥ 3 | 31 (16 to 63) | ||
| CI: confidence interval; G: International Society of Urological Pathology grade; MRI: magnetic resonance imaging; MRI‐pathway: magnetic resonance imaging with or without magnetic resonance imaging‐targeted biopsy; N: number; NA: not applicable; NNB: number needed to biopsy; SBx: systematic biopsy | |||
aNumber needed to biopsy by systematic biopsy is 100 divided by the added value of systematic biopsy.